{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-213239","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.980232+00:00","generated_at":"2026-05-14T21:09:40.638894+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M","bullets":["71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.","FDA aligned on single Phase 3 registrational trial for AlloNK in ~150 refractory RA patients; ACR50 at 6 months primary endpoint.","Safety: no CRS, ICANS, or AlloNK-related discontinuations; outpatient administration in community rheumatology clinics.","Q1 net loss $23.5M; cash $86.8M expected to fund operations into Q2 2027.","ATM sales suspended under Sales Agreement with Leerink; agreement remains in effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213239","json":"https://secwatch.observer/filing/0001193125-26-213239.json","markdown":"https://secwatch.observer/filing/0001193125-26-213239.md","text":"https://secwatch.observer/filing/0001193125-26-213239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:09:40.638894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a9f5b1e90b1272633f47368cbbe4f1d2476521b","claim":"Artiva Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"Artiva Biotherapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}